Your account is not claimed yet. You can sign up with ORCID to claim your account.

Hiroyuki Seimiya

Researcher Name Resolver ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 16

Top Venues

Cancer science

Scientific reports

The Journal of biological chemistry

Proceedings of the National Academy of Sciences of the United States of America

This page only lists publications with an associated author ORCID identifier.

Publications

Yoshihiro Mezawa, Tingwei Wang, Yataro Daigo, Atsushi Takano, Yohei Miyagi, Tomoyuki Yokose, Toshinari Yamashita, Liying Yang, Reo Maruyama, Hiroyuki Seimiya, Akira Orimo
Glutamine deficiency drives transforming growth factor-β signaling activation that gives rise to myofibroblastic carcinoma-associated fibroblasts. Cancer science (2023)
Masatomo Chiba, Kenichi Miyata, Hikaru Okawa, Yoko Tanaka, Koji Ueda, Hiroyuki Seimiya, Akiko Takahashi
YBX1 Regulates Satellite II RNA Loading into Small Extracellular Vesicles and Promotes the Senescent Phenotype. International journal of molecular sciences 24 (22) (2023)
Mingjue Chen, Tetsuo Mashima, Taichi Oishi, Yukiko Muramatsu, Yosuke Seto, Manabu Takamatsu, Naomi Kawata, Shun Morino, Ayane Nakamura, Saori Inaba, Xunmei Yuan, Kohei Maruyama, Mai Suzuki, Ayana Sato, Haruka Yoshida, Myung-Kyu Jang, Anna Mizutani, Kengo Takeuchi, Kensei Yamaguchi, Fumiyuki Shirai, Satoshi Nagayama, Ryohei Katayama, Hiroyuki Seimiya
APC/PIK3CA mutations and β-catenin status predict tankyrase inhibitor sensitivity of patient-derived colorectal cancer cells. British journal of cancer (2023)
Caroline Moyret-Lalle, Mélanie K Prodhomme, Delphine Burlet, Ayaka Kashiwagi, Virginie Petrilli, Alain Puisieux, Hiroyuki Seimiya, Agnès Tissier
Role of EMT in the DNA damage response, double-strand break repair pathway choice and its implications in cancer treatment. Cancer science 113 (7) (2022)
Naoyuki Nishiya, Yusuke Oku, Chie Ishikawa, Tsutomu Fukuda, Shingo Dan, Tetsuo Mashima, Masaru Ushijima, Yoko Furukawa, Yuka Sasaki, Keishi Otsu, Tomoko Sakyo, Masanori Abe, Honami Yonezawa, Fumito Ishibashi, Masaaki Matsuura, Akihiro Tomida, Hiroyuki Seimiya, Takao Yamori, Masatomo Iwao, Yoshimasa Uehara
Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor. Cancer science 112 (5) (2021)
Hiroyuki Seimiya, Kazuo Nagasawa, Teppei Kawahara
Chemical targeting of G-quadruplexes in telomeres and beyond for molecular cancer therapeutics. The Journal of antibiotics 74 (10) (2021)
Kyoko Matsumoto, Keiji Okamoto, Sachiko Okabe, Risa Fujii, Koji Ueda, Kenichi Ohashi, Hiroyuki Seimiya
G-quadruplex-forming nucleic acids interact with splicing factor 3B subunit 2 and suppress innate immune gene expression. Genes to cells : devoted to molecular & cellular mechanisms 26 (2) (2021)
Kenichi Miyata, Yoshinori Imai, Satoshi Hori, Mika Nishio, Tze Mun Loo, Ryo Okada, Liying Yang, Tomoyoshi Nakadai, Reo Maruyama, Risa Fujii, Koji Ueda, Li Jiang, Hao Zheng, Shinya Toyokuni, Toyonori Sakata, Katsuhiko Shirahige, Ryosuke Kojima, Mizuho Nakayama, Masanobu Oshima, Satoshi Nagayama, Hiroyuki Seimiya, Toru Hirota, Hideyuki Saya, Eiji Hara, Akiko Takahashi
Pericentromeric noncoding RNA changes DNA binding of CTCF and inflammatory gene expression in senescence and cancer. Proceedings of the National Academy of Sciences of the United States of America 118 (35) (2021)
Satoshi Matsusaka, Diana L Hanna, Yan Ning, Dongyun Yang, Shu Cao, Martin D Berger, Yuji Miyamoto, Mitsukuni Suenaga, Shingo Dan, Tetsuo Mashima, Hiroyuki Seimiya, Wu Zhang, Heinz-Josef Lenz
Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib. Cancer science 111 (2) (2020)
Ryuhei Kawakami, Tetsuo Mashima, Naomi Kawata, Koshi Kumagai, Toshiro Migita, Takeshi Sano, Nobuyuki Mizunuma, Kensei Yamaguchi, Hiroyuki Seimiya
ALDH1A3-mTOR axis as a therapeutic target for anticancer drug-tolerant persister cells in gastric cancer. Cancer science 111 (3) (2020)
Keiji Okamoto, Hiroyuki Seimiya
From the wings to the center stage of chromosomes. The Journal of biological chemistry 294 (47) (2020)
Hiroyuki Seimiya
Crossroads of telomere biology and anticancer drug discovery. Cancer science 111 (9) (2020)
Myung-Kyu Jang, Tetsuo Mashima, Hiroyuki Seimiya
Tankyrase Inhibitors Target Colorectal Cancer Stem Cells via AXIN-Dependent Downregulation of c-KIT Tyrosine Kinase. Molecular cancer therapeutics 19 (3) (2020)
Tomohisa Hatta, Shun-Ichiro Iemura, Tomokazu Ohishi, Hiroshi Nakayama, Hiroyuki Seimiya, Takao Yasuda, Katsumi Iizuka, Mitsunori Fukuda, Jun Takeda, Tohru Natsume, Yukio Horikawa
Calpain-10 regulates actin dynamics by proteolysis of microtubule-associated protein 1B. Scientific reports 8 (1) (2018)
Chiaki Fujiwara, Yukiko Muramatsu, Megumi Nishii, Kazuhiro Tokunaka, Hidetoshi Tahara, Masaru Ueno, Takao Yamori, Yoshikazu Sugimoto, Hiroyuki Seimiya
Cell-based chemical fingerprinting identifies telomeres and lamin A as modifiers of DNA damage response in cancer cells. Scientific reports 8 (1) (2018)
Anna Mizutani, Yoko Yashiroda, Yukiko Muramatsu, Haruka Yoshida, Tsubasa Chikada, Takeshi Tsumura, Masayuki Okue, Fumiyuki Shirai, Takehiro Fukami, Minoru Yoshida, Hiroyuki Seimiya
RK-287107, a potent and specific tankyrase inhibitor, blocks colorectal cancer cell growth in a preclinical model. Cancer science 109 (12) (2018)

Hiroyuki Seimiya.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Hiroyuki Seimiya